Deeter Investments’s BridgeBio Pharma BBIO Stock Holding History

Deeter Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$3.71M	–	104
2026 Q1	$3.71M	Sell	50,000 -33,000	-40%	-$2.39M	0.42%	47
2025 Q4	$6.35M	Buy	+83,000	New	+$5.45M	1.36%	24

Other funds holding BBIO

Jupiter Topco New York $245B AUM

Kohlberg Kravis Roberts & Co New York $5.04B AUM 56.8% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

Deeter Investments's BBIO Position: Q2 2026 in Review

Deeter Investments sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 50,000 shares — an estimated $3.71M sold.

Deeter Investments first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $6.35M in Q4 2025. 477 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Deeter Investments reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Deeter Investments sold 50,000 BridgeBio Pharma shares in Q2 2026, an estimated $3.71M.
Deeter Investments first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
Deeter Investments's BridgeBio Pharma position peaked at $6.35M in Q4 2025.
477 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.